Preimplantation Genetic Diagnosis Policy Debate Framed In Extremes; Public Favors Government Assurance That PGD Is Safe And Effective

Navigate to:

Preimplantation Genetic Diagnosis Policy Debate Framed In Extremes; Public Favors Government Assurance That PGD Is Safe And Effective

While the loudest voices in the debate over preimplantation genetic diagnosis (PGD) focus either on restricting PGD or on letting families decide for themselves whether to use PGD, this framing "fails to reflect the public's more nuanced views" argues Kathy Hudson, director of the Genetics and Public Policy Center in the June 2006 issue of the journal Fertility and Sterility. The public's greater concern is that the government needs to make sure that PGD is safe and effective, she writes.

Hudson's paper is based on a series of focus groups, in-depth interviews, and surveys conducted for the Genetics and Public Policy Center between October 2002 and August 2004 with a combined sample size of more than 6,000. The Center is supported at The Johns Hopkins University by The Pew Charitable Trusts.

The paper summarizes the regulatory framework surrounding PGD, which involves removing one or two cells from a six- to eight-cell embryo created through in vitro fertilization. Each cell can be analyzed to detect either a chromosome or single gene disorder, or a specific genetic characteristic such as sex. Very little direct oversight of PGD currently exists, Hudson found, even though the test is increasingly being used by parents to identify and select the inherited characteristics of their children before pregnancy. More than 2,000 children have been born following PGD.

The policy debate about PGD and similar reproductive technologies is stunted because it is currently cast in the same terms as the abortion rights debate, Hudson notes, even though the Center's research revealed a much more ambivalent public. For example, some people who feel that an embryo has the same moral status as a born baby nonetheless feel that it is morally acceptable to use PGD to test embryos for certain diseases and not transfer an embryo to a mother's womb if it is found to have a genetic disorder.

"This divisiveness around embryo politics...means that the public's desire for oversight of the safety and accuracy of PGD is left unattended," Hudson maintains. While the public's views should not be the only driver of public policy, she says, "attentiveness to these views could help redefine and reframe the policy debate to address more productively some of our shared concerns about the development and use of PGD."

Full Citation:
Hudson, K. Preimplantation genetic diagnosis: public policy and public attitudes. Fertility and Sterility Vol. 85, No. 6, June 2006.

Pew is no longer active in this line of work, but for more information, visit the Genetics & Public Policy Center Web site or visit the Genetics and Public Policy Centeron PewHealth.org.

America’s Overdose Crisis
America’s Overdose Crisis

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Quick View

America’s Overdose Crisis

Sign up for our five-email course explaining the overdose crisis in America, the state of treatment access, and ways to improve care

Sign up
Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.